BioSpace

Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms

On its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertension drug Winrevair that drove the pharma’s overall sales expectations to surpass expectations.

By BioSpace

1 min read
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights